TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04919330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Acceptance and Commitment Therapy-based Eczema Management Programme
Description: The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation.
Study: NCT06404970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening intervention
Description: Intervention to improve identification and management of functional impairment among older Veterans in VA primary care settings. Intervention includes 5 components: (1) routine, standardized functional status measurement; (2) nursing screening followed by follow-up primary care provider assessment; (3) electronic tools and templates to facilitate screening, assessment, and documentation; (4) interprofessional educational session; (5) tailored reports on functional status

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening intervention
Description: Intervention to improve identification and management of functional impairment among older Veterans in VA primary care settings. Intervention includes 5 components: (1) routine, standardized functional status measurement; (2) nursing screening followed by follow-up primary care provider assessment; (3) electronic tools and templates to facilitate screening, assessment, and documentation; (4) interprofessional educational session; (5) tailored reports on functional status

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bundle of implementation strategies
Description: Standard strategies include champions plus system-level audit and feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced bundle of implementation strategies
Description: Enhanced strategies include technical assistance plus clinician-level audit and feedback
Study: NCT05864703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjustment
Description: Instrument-assisted, high velocity, low amplitude adjustment
Study: NCT05019339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy HomeStyles
Description: Comparison of 2 educational interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eat Healthy Be Active
Description: Comparison of 2 educational interventions
Study: NCT04286373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active stimulation then placebo stimulation
Description: The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The two stimulation periods will be separated by a 4 weeks wash-out period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo stimulation then active stimulation
Description: VNS placebo stimulation will be performed under the same conditions and parameters as active VNS stimulation, but at a different site: the left ear lobule according to previously published methods (Fang et al. 2017, Frangos et al. 2015).~The active VNS stimulation will be applied in the hollow of the left outer ear on the auricular branch of the vagus nerve (cymba conchae), a session of 1 hour of stimulation per week, at a weak intensity value (between 2 to 5 mA), depending on the tolerance of each patient.~A transcutaneous vagus nerve stimulator Tens Eco Plus SCHWA MEDICO™ France with the Garches Azabou-Bao vagal electrode (the G electrode) will be used in this Clinical Investigation.~The two stimulation periods will be separated by a 4 weeks wash-out period.
Study: NCT04486352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 28 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 28 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 28 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 28 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab - 21 Day Cycle
Description: Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
Study: NCT04633759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Exercise
Description: Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
Study: NCT05326087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Description: oral MPA 10mg qd from Day 3 of ovarian stimulation till the day of ovulation trigger.
Study: NCT05448703

Intervention type: OTHER
Intervention: Blood Samples for Biomarkers
Description: blood sample to be taken at baseline, during radiotherapy, and after radiotherapy
Study: NCT04669899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-8064
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimivalimab
Description: Specified dose on specified days
Study: NCT04919330

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control Group
Description: The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
Study: NCT05157464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
Study: NCT06540859

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Non-invasive electrical stimulation of a lower extremity muscle group over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver sham stimulation. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention.
Study: NCT04486352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
Study: NCT06537492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: The REBOA device used in this study will be a computer-aided aortic balloon occlusion catheter with safety feedback and automatic inflation and deflation. The device will be used to temporarily inflate a balloon in the descending aorta through a femoral artery introducer sheath which, when inflated, redirects blood flow to the central circulation.~The REBOA will be inserted into the aorta via the femoral artery through an introducer sheath. Once positioned, the balloon will be inflated to occlude the aorta. The REBOA assistant will be attached to the patient's skin with the adhesive on the underside of the assistant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head-Up Cardiopulmonary Resuscitation (AHUP-CPR)
Description: Conventional CPR will be performed using an automated head and chest elevation device during cardiopulmonary resuscitation (AHUP-CPR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Chest Compression Device with Active Chest Decompression
Description: In addition to head and thorax elevation, mechanical chest compression will be performed with active chest compression-decompression using a specific mechanical chest compression device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device
Description: In addition to REBOA, AHUP-CPR and ACD, an impedance threshold device will be used with a dedicated device.
Study: NCT05864703

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Instrument-assisted light touch to neck
Study: NCT05926336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
Study: NCT06411626

Intervention type: OTHER
Intervention: PNH-relevant therapies
Description: This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
Study: NCT05738213

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Thermal stimuli
Description: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal stimuli
Description: The Thermal Sensory Analyzer (TSA-II or PATHWAY platform - Medoc, Ramat Yishai, Israel) will be used to safely deliver heat and cold stimuli. These devices can deliver relatively complex stimuli via computer control. All targeted stimulus temperatures will be less than 50°C, and participants will be free to remove their arm or leg at any time from the thermode. Noxious cold stimuli will also be delivered with a plastic water container or a water bath (FISHER, USA). Participants will be free to pull out of the water bath at any time.
Study: NCT05061667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Paravertebral block for postoperative analgesia in thoracic surgery
Study: NCT06025357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline supplementation
Description: 4 weeks of L-Citrulline supplementation (10 grams/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 weeks of microcrystalline Cellulose supplementation.
Study: NCT05738213

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pressure stimuli
Description: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure stimuli
Description: Pressure stimuli will be applied by using a handheld algometer (Wagner Instruments) or the Pressure Algometer (Medoc, Ramat Yishai, Israel). These devices have a round probe that allows quantifying the amount of pressure that is being applied. The Pressure Algometer allows a real-time visual feedback to control and monitor applied pressure rates. Pressure will be applied to the lower leg, volar forearm, or trapezius.
Study: NCT04540744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of macitentan/tadalafil (10 mg/20 mg)
Description: FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of macitentan/tadalafil (10 mg/20 mg)
Description: FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Description: Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Description: Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
Study: NCT04657146

Intervention type: OTHER
Intervention: Biorepository
Description: Tumor collection (\> 1cm3): Intraoperatively~Peripheral blood collection:~* Intraoperatively (60mL)~* Post-resection (30mL)~* Post- standard of care treatment (30mL)~Bone marrow aspiration:~* Intraoperatively (10mL)~* Post-resection (5mL)~* Post- standard of care treatment (5mL)
Study: NCT06441682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study: NCT06344312

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yangxue Qingnao Granules
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao Granules
Description: When receiving intravenous thrombolysis with ateplase, two bags of Yangxue Qingnao Granule Simulator were randomly taken orally. Afterwards, one bag of Yangxue Qingnao Granule/ Simulator was taken three times a day for a total of two weeks.
Study: NCT05061667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Block
Description: Rhomboid block for postoperative analgesia in thoracic surgery
Study: NCT05662852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Suspension manufactured by Sanofi Pasteur
Study: NCT06047795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy.
Study: NCT05166577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat
Description: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week